2-氨基-5-[(5-硝基-2-噻唑基)硫代]-1,3,4-噻二唑
2-氨基-5-[(5-硝基-2-噻唑基)硫代]-1,3,4-噻二唑
![2-氨基-5-[(5-硝基-2-噻唑基)硫代]-1,3,4-噻二唑 结构式](https://img.chemicalbook.com/CAS/GIF/40045-50-9.gif)
2-氨基-5-[(5-硝基-2-噻唑基)硫代]-1,3,4-噻二唑 性质
| 熔点 | 160 °C(dec.) |
|---|---|
| 沸点 | 549.8±42.0 °C(Predicted) |
| 密度 | 1.88±0.1 g/cm3(Predicted) |
| 储存条件 | Store at RT |
| 溶解度 | DMSO：62.5 mg/mL（239.19 mM；需要超声波） |
| 形态 | 淡黄色固体 |
| 酸度系数(pKa) | 0.65±0.10(Predicted) |
| 颜色 | 淡黄色至琥珀色至深绿色 |
| InChI | InChI=1S/C5H3N5O2S3/c6-3-8-9-5(14-3)15-4-7-1-2(13-4)10(11)12/h1H,(H2,6,8) |
| InChIKey | NQQBNZBOOHHVQP-UHFFFAOYSA-N |
| SMILES | S1C(SC2=NC=C([N+]([O-])=O)S2)=NN=C1N |
2-氨基-5-[(5-硝基-2-噻唑基)硫代]-1,3,4-噻二唑 用途与合成方法
IC50: 0.7 μM (JNK); 239 nM (JNK-JIP interactions)
SU3327 (compound 9) is able to inhibit TNF-α stimulated phosphorylation of c-Jun in HeLa cells (EC
50
= 6.23 μM).
SU3327 (25 nM) pretreatment of human-derived cerebral microvascular endothelial cells (hCMEC/D3) effectively reduces LPS-induced polymorphonuclear leukocytes (PMN) rolling/adhesion to hCMEC/D3, prevents activation of AP-1, and significantly reduces expression of VCAM-1.
SU3327 (Compound 9; 25 mg/kg; intraperitoneal injection; male BKS.Cg-+Lepr
db
/+Lepr
db
/OlaHsd db/db mice) treatment possesses the ability to restore insulin sensitivity in mice models of diabetes.
SU3327 (Compound 9) has favorable microsomal and plasma stability (T
1/2
= 27 min).
| Animal Model: | Male BKS.Cg-+Lepr db /+Lepr db /OlaHsd db/db mice (11-week-old ) injected with insulin |
| Dosage: | 25 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Resulted in a statistically significant reduction in blood glucose levels. |
2-氨基-5-[(5-硝基-2-噻唑基)硫代]-1,3,4-噻二唑 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-12-22 | HY-107597 | 2-氨基-5-[(5-硝基-2-噻唑基)硫代]-1,3,4-噻二唑 | 40045-50-9 | 1 mg | 300 |
| 2025-12-22 | HY-107597 | 2-氨基-5-[(5-硝基-2-噻唑基)硫代]-1,3,4-噻二唑 | 40045-50-9 | 5mg | 750 |
